SWOG clinical trial number
CTSU/ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Open
Phase
Abbreviated Title
Randomized ph III study of Nivo + chemo-immunotherapy for newly dx primary mediastinal B-lymph
Status Notes
CTSU/ANHL1931 was temporarily closed to accrual on 6/24/21.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.
Activated
06/07/2021
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lymphoma
Treatment
Cyclophosphamide
Prednisone
Vincristine
Doxorubicin
Etoposide
Rituximab
Nivolumab
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Research Committee(s)
Lymphoma
Activated
06/07/2021
Open
Phase
SWOG Clinical Trial Number
S1918
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Research Committee(s)
Lymphoma
Activated
03/19/2021
Accrual
6%
Open
Phase
II-III
SWOG Clinical Trial Number
CTSU/EA4181
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
10/03/2019
Open
Phase
II